F-star Therapeutics, Inc. financial data

Industry
Pharmaceutical Preparations
Location
35 Parkwood Drive, Babraham Research Campus, Cambridge, United Kingdom
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Spring Bank Pharmaceuticals, Inc. (to 11/9/2020)
Latest financial report
10-Q - Q3 2022 - Nov 10, 2022

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 505 % +25.5%
Debt-to-equity 34.6 % +2.85%
Return On Equity -57.1 % +14.4%
Return On Assets -42.4 % +15.1%
Operating Margin -174 % +84.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 22M shares +6.58%
Common Stock, Shares, Outstanding 22M shares +6.59%
Common Stock, Value, Issued 2K USD 0%
Weighted Average Number of Shares Outstanding, Basic 21.9M shares +6.01%
Weighted Average Number of Shares Outstanding, Diluted 21.9M shares +6.01%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 21.2M USD +453%
Revenue from Contract with Customer, Excluding Assessed Tax 1.13M USD +49.8%
Research and Development Expense 34.6M USD +45.3%
General and Administrative Expense 23.3M USD -2.98%
Costs and Expenses 57.9M USD +21.1%
Operating Income (Loss) -36.8M USD +16.5%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -45.3M USD -70.6%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -44.7M USD -0.4%
Earnings Per Share, Basic -0.84 USD/shares -61.5%
Earnings Per Share, Diluted -0.84 USD/shares -61.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 35.6M USD -49.9%
Assets, Current 49.6M USD -34.9%
Property, Plant and Equipment, Net 879K USD -13.1%
Operating Lease, Right-of-Use Asset 2.5M USD -28.6%
Intangible Assets, Net (Excluding Goodwill) 16.2M USD -13.8%
Goodwill 14.1M USD -5.16%
Other Assets, Noncurrent 412K USD -8.44%
Assets 83.7M USD -27.1%
Accounts Payable, Current 2.5M USD +59.4%
Employee-related Liabilities, Current 1.76M USD +22.2%
Accrued Liabilities, Current 7.75M USD +37.3%
Liabilities, Current 14.7M USD +66.1%
Operating Lease, Liability, Noncurrent 2.01M USD -30%
Liabilities 26.8M USD +8.33%
Accumulated Other Comprehensive Income (Loss), Net of Tax 1.57M USD
Retained Earnings (Accumulated Deficit) -128M USD -53.8%
Stockholders' Equity Attributable to Parent 56.9M USD -36.8%
Liabilities and Equity 83.7M USD -27.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -11.6M USD +19.2%
Net Cash Provided by (Used in) Financing Activities 1.88M USD
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 22M shares +6.59%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -9.74M USD +33.5%
Interest Paid, Excluding Capitalized Interest, Operating Activities 238K USD
Depreciation 122K USD -15.3%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -42M USD +5.53%
Lessee, Operating Lease, Liability, to be Paid 2.84M USD -38.5%
Property, Plant and Equipment, Gross 2.58M USD +0.16%
Operating Lease, Liability, Current 826K USD -15.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 393K USD -60.3%
Lessee, Operating Lease, Liability, to be Paid, Year One 829K USD -15.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 382K USD -19.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 372K USD -23.5%
Additional Paid in Capital 183M USD +5.1%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 100K USD 0%
Share-based Payment Arrangement, Expense 5.66M USD -17.3%
Interest Expense 1.34M USD +16.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%